Literature DB >> 30782703

Features and trends of thyroid cancer in patients with thyroidectomies in Beijing, China between 1994 and 2015: a retrospective study.

Ling Zhao1, Ping Pang2, Li Zang1, Yukun Luo3, Fulin Wang4, Guoqing Yang1, Jin Du1, Xianling Wang1, Zhaohui Lyu1, Jingtao Dou1, Yiming Mu1.   

Abstract

OBJECTIVES: This study aims to summarise the features and trends of thyroid carcinoma in the past two decades in China. DESIGN, SETTING AND PARTICIPANTS: Clinical data obtained from 10 798 patients treated by thyroidectomy from 1994 to 2015 at the Department of General Surgery of the People's Liberation Army General Hospital, Beijing, China were retrospectively analysed. OUTCOME MEASURES: Incidence and histopathological features of thyroid cancer were compared and the risk factors for local lymph node metastasis analysed.
RESULTS: Our data indicated a significant increase in the detection of thyroid cancer (from 16.8% to 69.8%, p<0.01). Among the 5235 thyroid cancer cases, papillary thyroid carcinoma (PTC) was the most common histotype, accounting for 95.1% of all malignancies over the 22-year period. Among the 4979 PTCs, micro-PTCs (mPTC) with the largest diameter ≤10 mm has gradually become the dominant form, and its percentage in PTCs has increased from 13.3% in the biennial period of 1994-1995 to 51.2% in 2010-2011. Furthermore, the size of the tumour has decreased significantly from 2.3±1.1 cm in 1994 to 1.2±0.9 cm in the largest diameter (p<0.01), while the average age at diagnosis and female dominance remained unchanged during the period. Logistic regression showed that tumour nodules>1 cm and male gender were the main risk factors for local lymph node metastasis (LNM), whereas patients over 45 years had lower risk.
CONCLUSIONS: During the 22-year period, an increased detection of thyroid cancer, particularly mPTC, was found while the occurrence of LNM decreased. Our results suggest that the current preoperative diagnosis and risk stratification are adequate, supporting the published guidelines for the diagnosis of thyroid cancer. © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  microptc; papillary thyroid carcinoma; thyroid cancer

Mesh:

Year:  2019        PMID: 30782703      PMCID: PMC6347868          DOI: 10.1136/bmjopen-2018-023334

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


The strength of this study lies in that >10 000 cases of thyroid cancer over a period of 22 years were retrospectively studied to summarise the features and trends of thyroid cancer in patients with thyroidectomies in Beijing, China. The clinical practice was reviewed over this long period of time to evaluate the performance of the preoperative diagnosis and risk stratification in a major hospital in Beijing. The retrospective nature of this study led to limited survival data, which should have been included to evaluate the improvement of clinical outcome during the 22-year period.

Introduction

Thyroid nodules occur in about 4%–7% of the population, and 8%–16% of these contain malignant elements.1 Thyroid cancer is the most common endocrine cancer,1 and approximately 90% of these are differentiated, including predominantly papillary thyroid carcinoma (PTC) and, to a less extent, follicular thyroid carcinoma.2 These subtypes are generally associated with a more favourable prognosis and higher cure rate,3 when compared with less common but more aggressive forms of thyroid cancer, such as medullary thyroid cancer, anaplastic thyroid cancer and thyroid sarcoma or lymphoma.4 The past few decades have witnessed an increase in the incidence of thyroid cancer, while the associated mortality remains unchanged.5–9 In addition, the number of newly diagnosed thyroid cancer cases with smaller tumours increased. Between 2008 and 2009, 39% of patients with thyroid cancer were diagnosed with tumours smaller than 1 cm, when compared with 25% of patients diagnosed between 1988 and 1989.10 This was due to the proactive screening of thyroid cancer, particularly through the application of sensitive surveillance modalities in recent years.11–15 Advanced imaging techniques, such as ultrasonography, CT, MRI and positron emission tomography, along with fine-needle aspiration biopsy have dramatically improved the detection of small thyroid nodules, and facilitated the early diagnosis of thyroid cancer.16–18 However, the increased incidence of thyroid cancer has also been considered to be associated with overdiagnosis18–22 and environmental factors.6 23 The screening of highly prevalent thyroid nodules for those with malignant potential remains challenging, although a number of guidelines have recently been proposed for the diagnosis and management of thyroid nodules.24 Identifying nodules with high risk of malignancy during thyroidectomy represents a cost-effective approach.25 26 Therefore, in this study, the features and trends of thyroid cancer in patients with thyroidectomies in China were retrospectively analysed to examine whether the decrease in diagnosable size of thyroid nodules is associated with misdiagnosis, providing further insight into its diagnosis and management.

Materials and methods

Written informed consent was obtained from all patients for retrospective studies.

Data collection

The clinical database for patients undergoing thyroidectomies from 1994 to 2015 at the Department of General Surgery of PLA General Hospital (Beijing, China) was revisited, and the thyroid pathology reports were screened and reviewed to analyse the correlation of the size of thyroid nodules with other pathological features. The clinical parameters used in the analysis included front neck discomfort or pain, dysphagia, dysphonia or hoarseness, dyspnoea, sign of thyroid nodule and thyroid gland enlargement, as well as ultrasound features. These data were individually checked, and cases with inconsistent data were excluded before the statistical analysis. As a result, 10 798 eligible cases with thyroidectomies from 1994 to 2015 were recruited.

Data analysis and statistics

Benign or malignant thyroid nodules were diagnosed based on pathological features, and malignant nodules were reported as PTC, follicular (FTC), medullary (MTC) or anaplastic thyroid carcinoma (ATC). PTCs were further subclassified into clinically relevant PTCs (crPTCs) >10 mm in diameter and micro-PTCs (mPTCs) ≤10 mm in diameter (the largest diameter of a nodule). These subgroups were compared, when appropriate, in the analysis. Patients were treated by surgery, often with lymph node dissection, depending on the clinical features and the number, location and size of the involved lymph node, which was assessed by preoperative imaging analysis and intraoperative frozen section pathological analysis. Tumours within 10 mm in size and had no involvement of lymph nodes were resected without the removal of lymph nodes. When the preoperative imaging revealed no abnormalities in the lymph nodes, but malignancy was confirmed by intraoperative frozen section analysis, ipsilateral central neck node dissection was performed. If the preoperative sonography or intraoperative examination revealed abnormal lymph nodes, and frozen section analysis confirmed the malignancy, improved lateral neck lymph node dissection was performed. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS, V.17.0; IBM, Armonk, New York, USA). Data were presented as mean±SD or mean±SE, when appropriate; Χ2 test was used to compare different categories and generate the trend lines. Furthermore, t-test was used for comparisons between groups, and logistic regression was performed to calculate the risk factors for lymph node metastasis (LNM). The data analysis was adjusted for confounders, such as age, gender, nodule size and the presence of Hashimoto thyroiditis. A two-tailed p<0.05 was considered to be statistically significant.

Patient and public involvement

This retrospective study did not involve patients or the public in the development of research initiatives and outcome measures, as well as the design and implementation of the study. The study covered a period of 22 years, which ranged between 1994 and 2015. Therefore, there was no possibility or plan to disseminate the results among the participants.

Results

Malignancy rate increased from 1994 to 2015

The numbers of benign and malignant cases of thyroid cancer detected during thyroidectomy from 1994 to 2015 are summarised in table 1. As the number of thyroidectomy surgeries increased due to the improved diagnosis of thyroid cancer, the number of benign and malignant cases gradually increased. Noticeably, the malignancy rate of thyroid nodules dramatically increased from 16.8% during the biennial period of 1994–1995 to 69.8% during the period of 2014–2015 (p<0.05), while the benign rate decreased from 83.2% to 30.2% (p<0.05).
Table 1

Detection rate of malignancy among patients undergoing thyroidectomy from 1994 to 2015

Period94–95*96–9798–9900–0102–0304–0506–0708–0910–1112–1314–15TotalP value
Benign, n (%)114 (83.2)136 (86.1)†‡169 (88.0)†‡268 (83.0)†286 (80.1)†‡495 (79.2)‡535 (71.4)†‡738 (64.6)†‡901 (52.4)†‡1033 (42.2)†‡890 (30.2)†‡5563 (51.5)<0.001
Cancer, n (%)23 (16.8)22 (13.9)*†23 (12.0)*†55 (17.0)*71 (19.9)*†130 (20.8)†214 (28.6)*†405 (35.4)*†817 (47.6)*†1413 (57.8)*†2060 (69.8)*†5235 (48.5)
Total137158192323357625749114317182446295010 798

*The last 2 digits of the years are displayed (hereafter).

†Percentages significantly different from the previous year.

‡Percentages significantly different within the period of 94–95.

Detection rate of malignancy among patients undergoing thyroidectomy from 1994 to 2015 *The last 2 digits of the years are displayed (hereafter). †Percentages significantly different from the previous year. ‡Percentages significantly different within the period of 94–95.

The diagnosis rate of PTC increased from 1994 to 2015

Among the 10 798 cases recruited, 5235 cases were found to be malignant (table 2). Furthermore, a majority of patients (63.6%) were found with multiple cancers. Moreover, 48.1% of patients had unilateral cancer, and the remaining 51.9% of patients had bilateral cancer (table 2). In addition, most of the malignant cases were recorded as PTCs, which exhibited a significant increase from 65.3% during the period of 1994–1995 to 98.2% during the period of 2014–2015 (p<0.05, figure 1), while the diagnosis rates of other histotypes concurrently decreased (table 2 and figure 1).
Table 2

Pathological classification of all thyroid malignancies from 1994 to 2015

Period94–9596–9798–9900–0102–0304–0506–0708–0910–1112–1314–15P for differenceP for trend
PTC, n (%)15 (65.3)17 (77.3)17 (73.9)39 (70.9)50 (70.4)107 (82.3)185 (86.4)383 (94.6)768 (94.0)1376 (97.4)2023 (98.2)<0.001<0.001
FTC, n (%)3 (13.0)1 (4.5)4 (17.3)10 (18.1)9 (12.7)17 (13.1)18 (8.4)9 (2.2)25 (3.0)17 (1.2)20 (0.9)<0.001<0.001
MTC, n (%)1 (4.3)2 (9.1)1 (4.3)4 (7.3)2 (2.8)1 (0.8)2 (0.9)5 (1.2)14 (1.7)12 (0.8)12 (0.6)<0.001<0.001
ATC, n (%)0 (0)0 (0)1 (4.3)1 (1.8)3 (4.2)1 (0.8)1 (0.5)2 (0.5)1 (0.1)1 (0.1)2 (0.1)<0.001<0.001
Other, n (%)4 (17.4)2 (9.1)0 (0)1 (1.8)7 (9.9)4 (3.1)7 (3.3)6 (1.5)9 (1.1)7 (0.5)3 (0.1)<0.001<0.001
Unilateral14 (60.9)14 (63.6)13 (56.5)31 (56.4)38 (53.5)72 (55.4)122 (57.0)213 (52.6)389 (47.6)616 (43.6)991 (48.1)0.071<0.001
Bilateral9 (39.1)8 (36.4)10 (43.5)24 (43.6)33 (46.5)58 (44.6)92 (43.0)192 (47.4)428 (52.4)797 (56.4)1069 (51.9)
Solitary7 (30.4)13 (59.1)11 (47.8)27 (49.1)28 (39.4)59 (45.4)105 (49.0)172 (42.5)292 (35.7)456 (32.3)749 (36.4)<0.001<0.001
Multiple16 (69.6)9 (40.9)12 (52.2)28 (50.9)43 (60.6)71 (54.6)109 (51.0)233 (57.5)525 (64.3)957 (67.7)1311 (63.6)
All cancer, n 232223557113021440581714132060

ATC, anaplastic thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; other histotypes of carcinoma collectively refer to cancer other than PTC, FTC, MTC and ATC, including poorly differentiated thyroid cancer, squamous cell carcinomas, B cell lymphomas of thyroid, spindle cell carcinoma, adenoid cystic carcinoma, renal clear cell metastasis and Langerhans cell histocytosis of the thyroid gland; PTC, papillary thyroid carcinoma.

Figure 1

Trends in the diagnosis of various subtype thyroid malignancies, presented as permillage (rate per thousand) of thyroid cancer, from 1994 to 2015. ATC, anaplastic thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; PTC, papillary thyroid carcinoma.

Trends in the diagnosis of various subtype thyroid malignancies, presented as permillage (rate per thousand) of thyroid cancer, from 1994 to 2015. ATC, anaplastic thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; PTCpapillary thyroid carcinoma. Pathological classification of all thyroid malignancies from 1994 to 2015 ATC, anaplastic thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; other histotypes of carcinoma collectively refer to cancer other than PTC, FTC, MTC and ATC, including poorly differentiated thyroid cancer, squamous cell carcinomas, B cell lymphomas of thyroid, spindle cell carcinoma, adenoid cystic carcinoma, renal clear cell metastasis and Langerhans cell histocytosis of the thyroid gland; PTC, papillary thyroid carcinoma.

Detection size of thyroid nodules decreased from 1994 to 2015

The review of the clinicopathological information of malignant cases suggested that most of these patients were free of clinically relevant symptoms and physical signs (figure 2A and B), and only 9% of patients exhibited different degrees of discomfort, such as pain and dysphagia. The enlargement of thyroid glands were often noticed, but not necessarily by health professionals, during routine physical examination. However, 34% of tumours were impalpable, which was likely due to the depth of the intrathyroidal microcarcinoma. By ultrasonography, 37% of patients were detected with single thyroid tumours, while the remaining patients had multiple lesions (figure 2C).
Figure 2

Clinical, surgical and ultrasound features during the evolvement of thyroidectomy and the diagnosis of thyroid cancer from 1994 to 2015. Data on the symptoms (A), physical signs (B), nodule multiplicity (C), ultrasonographic sizes of nodules (D), fine-needle aspiration ratio (E) and thyroidectomy types (F) were summarised.

Clinical, surgical and ultrasound features during the evolvement of thyroidectomy and the diagnosis of thyroid cancer from 1994 to 2015. Data on the symptoms (A), physical signs (B), nodule multiplicity (C), ultrasonographic sizes of nodules (D), fine-needle aspiration ratio (E) and thyroidectomy types (F) were summarised. From 1994 to 2015, the size of thyroid nodules has been reported to significantly decrease, with the mean diameter reduced from 2.6±1.4 cm to 1.2±0.9 cm (figure 2D). This trend roughly correlates with the increase in the rate of preoperative fine-needle aspiration (FNA), which ranged from 15% in 2004 to 74% in 2013, although this rate regressed to 57% between 2014 and 2015 (figure 2E). In addition, during the same period, the total thyroidectomy rate remained unchanged from 1994 to 2007, but gradually increased from 2008 to 2013, and decreased sharply to 3% from 2014 to 2015 (figure 2F).

The size of the thyroid cancer at diagnosis and metastasis rate decreased from 1994 to 2015

Considering the high prevalence of PTCs, 4980 cases were compared with 255 cases of other subtypes all-together, and further data analysis was restricted to this type of thyroid cancer. As shown in table 3, the mean age of patients at diagnosis was 43.7±11.3 years, with no significant variation from 1994 to 2015. Furthermore, the incidence of PTC was considerably higher in women than in men, in which approximately two-thirds of these patients were female. It is noteworthy that the average diameter of PTCs at diagnosis decreased from 2.3±1.1 cm in 1994 to 1.2±0.9 cm in 2015 (p<0.05, table 3). Correlating with this trend was the increase in the percentage of mPTCs from 13.3% between 1994 and 1995 to 51.2% between 2010 and 2011 (p<0.05, table 3). This likely resulted from a more meticulous pathological examination. Interestingly, the detection rate of mPTCs decreased to 26.5 between 2014 and 2015.
Table 3

Clinicopathological features of PTCs from 1994 to 2015

Period94–9596–9798–9900–0102–0304–0506–0708–0910–1112–1314–15TotalP for differenceP for trend
Age, year46.9±14.343.1±10.741.1±12.944.9±14.844.6±14.543.8±12.444.6±12.442.7±12.443.9±11.243.9±11.143.6±10.943.7±11.30.643
Male, n (%)5 (33.3)3 (17.6)6 (35.3)11 (28.2)18 (36)34 (31.8)60 (32.4)115 (30.0)227 (29.6)366 (26.6)616 (30.4)1461 (29.3)0.4340.664
Female, n (%)10 (66.7)14 (82.4)*†11 (64.7.0)*28 (71.8)*32 (64)*†73 (68.2)†125 (67.6)*†268 (70.0)*†541 (70.4)*†1010 (73.4)*1407 (69.6)*3519 (70.7)
Size‡, cm2.3±1.12.6±1.92.1±1.32.2±1.62.2±1.42.2±1.61.7±1.1*†1.5±1.0b1.3±0.9*†1.2±0.8*†1.2±0.9†1.4±1.0<0.001
crPTC, n (%)13 (86.7)15 (88.2)12 (70.6)32 (82.1)41 (82.0)87 (81.3)118 (63.8)*238 (62.1)†375 (48.8)*†696 (50.6)b1486 (73.5)*3113 (62.5)<0.0010.213
mPTC, n (%)2 (13.3)2 (11.8)5 (29.4)7 (17.9)9 (18.0)20 (18.7)67 (36.2)145 (37.9)393 (51.2)680 (49.4)537 (26.5)1866 (37.5)
LNM, n (%)5 (33.3)5 (29.4)7 (41.2)22 (56.4)17 (34)27 (25.2)55 (29.7)96 (25.1)192 (25.0)372 (27.0)414 (20.5)*1212 (24.3)<0.001<0.001
No-LNM, n (%)10 (66.7)12 (70.6)10 (58.8)17 (43.6)33 (66)80 (74.8)130 (70.3)287 (74.9)576 (75.0)1004 (73.0)1609 (79.5)3768 (75.7)
Total151717395010718538376813762023<0.001<0.001

*Percentages significantly different from the previous year.

†Percentages significantly different within the period of 08–09.

‡Mean diameter.

crPTC, clinical relevant papillary thyroid carcinoma; LN, lymph node; LNM, lymph node metastasis; mPTC, micropapillary thyroid carcinoma.

Clinicopathological features of PTCs from 1994 to 2015 *Percentages significantly different from the previous year. †Percentages significantly different within the period of 08–09. ‡Mean diameter. crPTC, clinical relevant papillary thyroid carcinoma; LN, lymph node; LNM, lymph node metastasis; mPTC, micropapillary thyroid carcinoma. Among the PTC cases studied, 1212 patients were found with LNM, but its occurrence significantly decreased with the reduction in tumour size (p<0.05, table 3). This was associated with the increased diagnosis rate of mPTCs, which shows an apparently lower LNM potential in comparison with crPTCs (table 4). Before 2007, the difference between the LNM rates of mPTC and crPTC were appreciable, but this not statistically significant most of time due to the limited size of the cohort. With the increase in PTC diagnosis after 2008, a significantly lower LNM occurrence was found for mPTCs, when compared with crPTCs (table 4).
Table 4

Rate of local lymph node metastasis in patients with crPTC and mPTC from 2008 to 2013

Period94–9596–9798–9900–0102–0304–0506–0708–0910–1112–1314–15TotalP for differenceP for trend
crPTC, n (%)3 (23.1)5 (33.3)6 (50.0)19 (59.4)17 (41.5)24 (27.6)35 (29.7)73 (30.7)130 (34.7)243 (34.9)330 (22.2)885 (28.4)<0.001<0.001
mPTC, n (%)2 (100)0 (0)1 (20.0)3 (42.9)0 (0)3 (15.0)20 (29.9)23 (16.0)62 (15.8)129 (19.0)84 (15.6)327 (17.5)0.0050.087
P value0.0320.3310.2520.4250.0170.2430.9780.0010.0000.0000.001

crPTC, clinical relevant papillary thyroid carcinoma; mPTC, micropapillary thyroid carcinoma.

Rate of local lymph node metastasis in patients with crPTC and mPTC from 2008 to 2013 crPTC, clinical relevant papillary thyroid carcinoma; mPTC, micropapillary thyroid carcinoma.

Determinant factors of local lymph node metastasis in PTC, mPTC and crPTC

To identify the risk factors for local LNM in PTC, mPTC and crPTC, a logistic regression analysis was performed. The results support the correlation of LNM with nodules >1 cm (OR 2.480, 95% CI 0.428 to 0.613; p<0.001) and male gender (OR 1.627, 95% CI 1.376 to 1.923; p<0.001), and its inverse correlation with the age of ≥45 years (OR 0.512, 95% CI 2.040 to 2.902; p<0.001) after adjustment for other covariates in all PTCs (figure 3A, table 2). Hashimoto’s thyroiditis presented no risk for LNM (figure 3A). Consistent data were also obtained from patients with mPTC and crPTC (figure 3B and C; tables 3 and 4).
Figure 3

Determinant factors of the lymph node metastasis of papillary thyroid carcinoma (PTC) (A), micropapillary thyroid carcinoma (mPTC) (B) and clinically relevant papillary thyroid carcinoma (crPTC) (C). Logistic regression was performed to define factors associated with local lymph node metastasis (LNM).

Determinant factors of the lymph node metastasis of papillary thyroid carcinoma (PTC) (A), micropapillary thyroid carcinoma (mPTC) (B) and clinically relevant papillary thyroid carcinoma (crPTC) (C). Logistic regression was performed to define factors associated with local lymph node metastasis (LNM).

Discussion

Thyroid cancer is diagnosed in nearly 300 000 people annually all over the world.27 Although these malignancies are mostly differentiated and generally associated with a good prognosis, the involvement of local lymph nodes is frequently observed. Proactive screening for malignancies from a substantial population of thyroid nodes and accurate histopathological stratification are crucial for the clinical decision and improvement of patient outcome. The present study reviewed 10 798 cases of thyroidectomy undertaken in a major hospital located in one of the most populated city in the world for a period of over 22 years, summarised the clinical features of 5235 cases of thyroid cancer, and analysed the trend of PTCs and risk factors for predicting LNM. Among these patients, about 20% were from Beijing, while the rest 80% were from other regions in China where the disease could not be diagnosed definitely in local hospitals. Therefore, our patient cohort generally represented all China even though bias towards the difficult cases might exist. The present analysis unveiled a gradual but significant increase in thyroid malignancy detection rate between the period of 1994 and 2015, which ranged from 16.8% to 69.8%. These percentages are generally within the wide-range detection rate (6.7%–56%) of thyroid cancer worldwide,25 28 29 although data between 2014 and 2015 was relatively higher than earlier periods. Furthermore, the detection rates varied across different centres, which were likely caused by the different guidelines and algorithms followed by physicians and surgeons. The increase in detection rate from 1994 to 2015 reflects the improvement in diagnosis, through the advances in imaging technology and the increasing use of FNA, together with the shift of routine node dissection towards therapeutic dissection in the treatment. In addition, the appropriate preoperative risk stratification of thyroid nodules, which was a result of improved clinical evaluation, thyroid function test, ultrasonography and molecular diagnosis in recent years, has diverted a lot of patients from thyroidectomy, contributing to the increased diagnosis of thyroid cancer. These data support published guidelines30 31 and highlights the importance of combining imaging, FNA, cytology and molecular diagnosis. However, the contribution of social and environmental stresses could not be ruled out, which is beyond the scope of the present retrospective study. It is noteworthy that the present study covered a period during which China was undergoing the largest scale of industrialisation in modern history. This inevitably led to dramatic social and environmental changes. Papillary carcinoma accounts for 95.1% of malignancies in the whole cohort, and reached as high as 98.2% among patients diagnosed between 2014 and 2015. These rates were comparable to the findings of another study performed in Nanjing, China,25 but were higher than those in other reports,32 which was likely due to the increase in PTCs, as previously suggested.33 The high detection rate for PTC was attributable to the increasing use of head and neck imaging, which detects subpalpable (yet potentially malignant) thyroid nodules, and ultrasound-guided FNA, which improves the preoperative detection of malignancy. With the use of neck ultrasonography and other diagnostic approaches, the average size of PTCs at diagnosis has significantly reduced from 2.3±1.1 cm in 1994 to 1.2±0.9 cm in 2015, and this was similar to the trends reported in previous studies.10 25 This progress allows for the early detection of thyroid cancer, which leads to the increasing trend of hemithyroidectomy, when compared with total thyroidectomy, and the intensified follow-up of patients with thyroid cancer in recent years in our practice following the American Thyroid Association (ATA) guidelines.30 31 33 However, the overdiagnosis and overtreatment of indolent diseases have been increasingly recognised. The most recent ATA guidelines suggest a more parsimonious evaluation of thyroid nodules and a more judicious use of thyroid cancer treatment, in order to minimise risk and maximise benefits to patients.33 The present data suggest that nodules >1 cm and the male gender predict a high risk of LNM, while the age of ≥45 years is associated with low LNM potentials, and this is consistent with a previous finding.25 Therefore, more attention is needed for these patients in future practice. However, in this single-centre study, factors taken into account for the logistic regression analysis were limited due to the retrospective nature of the study. Future studies are needed to characterise the association of other clinical and biochemical parameters with thyroid cancer metastasis and patient outcome. Characterising the contribution of social and environmental stresses to the occurrence of thyroid cancer would also be of significant social economical value. In the present study, the clinical data of 10 798 patients treated by thyroidectomy was retrospectively analysed to determine the features and trends of thyroid cancer in the past 22 years. The present data suggested a significant increase in the detection rate of thyroid cancer, particularly mPTC, which has become the dominant form of thyroid cancer. As a result, the occurrence of LNM has been decreasing with time. The present results suggest the adequacy of present preoperative diagnosis and risk stratification, although overdiagnosis and overtreatment require future attention of physicians and surgeons in view of the rapid increase in the number of thyroidectomies.
  32 in total

1.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Steven I Sherman; R Michael Tuttle
Journal:  Thyroid       Date:  2006-02       Impact factor: 6.568

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Thyroid cancer: an epidemic of disease or an epidemic of diagnosis?

Authors:  Silvia Franceschi; Salvatore Vaccarella
Journal:  Int J Cancer       Date:  2014-11-12       Impact factor: 7.396

4.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

5.  Geographic Distribution and Evolution of Thyroid Cancer Epidemic in South Korea.

Authors:  Juan P Brito; Hyun Jung Kim; Seung Jin Han; Young Sung Lee; Hyeong Sik Ahn
Journal:  Thyroid       Date:  2016-04-01       Impact factor: 6.568

6.  The management of thyroid nodules: a retrospective analysis of health insurance data.

Authors:  Romy Wienhold; Markus Scholz; J Rgen-Bernhard Adler; Christian G Nster; Ralf Paschke
Journal:  Dtsch Arztebl Int       Date:  2013-12-06       Impact factor: 5.594

Review 7.  Rare Thyroid Malignancies: an Overview for the Oncologist.

Authors:  D B Spielman; A Badhey; S Kadakia; J C Inman; Y Ducic
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-02-24       Impact factor: 4.126

8.  Current thyroid cancer trends in the United States.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

9.  Ultrasound sensitivity for thyroid malignancy is increased by real-time elastography: a prospective multicenter study.

Authors:  Pierpaolo Trimboli; Rinaldo Guglielmi; Salvatore Monti; Irene Misischi; Filomena Graziano; Naim Nasrollah; Stefano Amendola; Sara Nazzarena Morgante; Maria Grazia Deiana; Stefano Valabrega; Vincenzo Toscano; Enrico Papini
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

10.  Thyroid cancer mortality and incidence: a global overview.

Authors:  Carlo La Vecchia; Matteo Malvezzi; Cristina Bosetti; Werner Garavello; Paola Bertuccio; Fabio Levi; Eva Negri
Journal:  Int J Cancer       Date:  2014-10-13       Impact factor: 7.396

View more
  7 in total

1.  Deep Learning-Based Recognition of Different Thyroid Cancer Categories Using Whole Frozen-Slide Images.

Authors:  Xinyi Zhu; Cancan Chen; Qiang Guo; Jianhui Ma; Fenglong Sun; Haizhen Lu
Journal:  Front Bioeng Biotechnol       Date:  2022-07-06

2.  Development and validation of the nomogram for predicting preoperative vocal cord palsy in thyroid cancer patients.

Authors:  Yunxiao Xiao; Zhenghao Wu; Shengnan Ruan; Yiquan Xiong; Tao Huang
Journal:  Gland Surg       Date:  2021-02

3.  The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine-Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment.

Authors:  Xiaojuan Zha; Zhenchun Miao; Xiu Huang; Xingchun Wang; Ruting Xie; Jiaoying Jin; Dajin Zou; Peng Yang; Yueye Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-07       Impact factor: 5.555

4.  Over-Expression and Prognostic Significance of FN1, Correlating With Immune Infiltrates in Thyroid Cancer.

Authors:  Qi-Shun Geng; Tao Huang; Li-Feng Li; Zhi-Bo Shen; Wen-Hua Xue; Jie Zhao
Journal:  Front Med (Lausanne)       Date:  2022-01-24

5.  Cervical lymph node metastases in papillary thyroid cancer: Preoperative staging with ultrasound and/or computed tomography.

Authors:  Guiling Lu; Liang Chen
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

6.  Differences in Clinicopathological Characteristics of Papillary Thyroid Carcinoma between Symptomatic and Asymptomatic Patients with Primary Hyperparathyroidism.

Authors:  Yuan Liu; Siyi Guo; Shaowei Sang; Jinbo Liu; Lin Qi; Bin Lv; Xiaoli Zhang
Journal:  Int J Endocrinol       Date:  2021-05-31       Impact factor: 3.257

7.  Clinical Analysis of Preoperative Anti-thyroglobulin Antibody in Papillary Thyroid Cancer Between 2011 and 2015 in Beijing, China: A Retrospective Study.

Authors:  Xiaomeng Jia; Ping Pang; Lin Wang; Ling Zhao; Lina Jiang; Yeqiong Song; Xiaojing Fan; Yajing Wang; Sitong Zhao; Jianming Ba; Guoqing Yang; Xianling Wang; Weijun Gu; Li Zang; Yu Pei; Jin Du; Yiming Mu; Zhaohui Lyu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-15       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.